Lilly’s Oral GLP-1 Candidate Outperforms AstraZeneca’s Farxiga in Late-Stage Diabetes Trials
Image
SHERIDAN, WYOMING – October 15, 2025 – Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, has achieved another major milestone in its late-stage clinical program. Following its earlier success against Novo Nordisk’s semaglutide, the once-daily oral therapy has now demonstrated superiority over AstraZeneca’s blockbuster Farxiga (dapagliflozin) in two Phase III studies targeting patients with inadequately controlled type 2 diabetes.